Forgot password?
   Please leave this field empty
Home | About Us | Careers | Contact Us | Shop | Connect:
Support Education Research
Please leave this field empty

FDA Approves Bayer's New Class of Drug to Treeat Adults with PAH

First and Only Drug Approved in United States to Treat Two Forms of Pulmonary Hypertension

Bayer HealthCare announced on Wednesday that the United States Food and Drug Administration (FDA) has approved Adempas® (riociguat) tablets for the treatment of adults with pulmonary arterial hypertension (PAH) and adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) to improve exercise capacity, improve WHO functional class, and delay clinical worsening.

Adempas is the only treatment approved in the U.S. for use in two types of pulmonary hypertension. It is the first and only FDA-approved drug therapy for persistent/recurrent CTEPH after surgical treatment or inoperable CTEPH.

Read the entire press release >>


All active news articles